Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Segment Reporting Information [Line Items]
Revenues	[1]	$ 27,742	$ 18,899	$ 53,402	$ 33,415
Income from continuing operations before provision/(benefit) for taxes on income	[2]	11,447	6,949	20,497	12,641
Net gains/(losses) recognized during the period on equity securities	[3],[4]	(541)	800	(1,241)	1,200
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income		69	62	125	89
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	317	437	655	827
Income from continuing operations before provision/(benefit) for taxes on income	[2],[5]	(3,441)	(2,524)	(5,917)	(4,571)
Inventory write-off		450		450
Reconciling Items [Member] | Amortization of Intangible Assets [Member]
Segment Reporting Information [Line Items]
Revenues		0	0	0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2]	(822)	(928)	(1,657)	(1,798)
Reconciling Items [Member] | Acquisition-Related Items [Member]
Segment Reporting Information [Line Items]
Revenues		0	0	0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2]	(82)	(34)	(269)	27
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	0	0	0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2],[6]	(1,431)	618	(2,322)	784
Net gains/(losses) recognized during the period on equity securities		(539)	798	(1,200)	1,200
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues	[1],[7]	27,425	18,463	52,748	32,588
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		27,425	18,463	52,748	32,588
Income from continuing operations before provision/(benefit) for taxes on income	[2]	$ 17,223	$ 9,816	$ 30,662	$ 18,199

[1] On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A.

[2] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $69 million in the second quarter of 2022 and $62 million in the second quarter of 2021, and $125 million in the first six months of 2022 and $89 million in the first six months of 2021.

[3] Reported in Other (income)/deductions––net. See Note 4.

[4] The losses in the second quarter and first six months of 2022 include, among other things, unrealized losses of $432 million and $776 million, respectively, related to investments in BioNTech and Cerevel Therapeutics Holdings, Inc. (Cerevel). The gains in the second quarter and first six months of 2021 included, among other things, unrealized gains of $917 million and $1.0 billion, respectively, related to investments in BioNTech and Cerevel.

[5] Other business activities include revenues and costs associated with PC1, as well as costs that we do not allocate to our operating segments, per above. Included in earnings in the second quarter and first six months of 2022 is a $450 million write-off to Cost of sales of inventory related to COVID-19 products that have exceeded or are expected to exceed their approved shelf-lives prior to being used.

[6] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). For earnings in the second quarter and first six months of 2022, includes, among other items, net losses on equity securities of $539 million and $1.2 billion, respectively, recorded in Other (income)/deductions––net. For earnings in the second quarter and first six months of 2021, includes, among other items, net gains on equity securities of $798 million and $1.2 billion, respectively, recorded in Other (income)/deductions––net.

[7] At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($55 million and $101 million for the second quarter and the first six months of 2022, respectively, and $87 million for both the second quarter and the first six months of 2021), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior-period information to conform to the current management structure.